Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
893 S Delaware St
Indianapolis, IN 46285
  • Featured Employer
Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
  • “Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”
    Kavita - Associate Director, Packaging Operations
  • “Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”
    Adrian - Associate Director, IDM
  • “What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”
    Cecile - Sr Director, Design Hub Foundations
39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.
NEWS
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease. Multiple drugs have failed in late-stage trials and some companies, such as Pfizer, have largely given up on the space.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Less than one year after it launched Cambridge, Mass.-based startup Sigilon Therapeutics struck a collaboration deal with Eli Lilly to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
More than a dozen advertisers, including Johnson & Johnson and Bayer, have boycotted the Fox News show, “The Ingraham Angle,” after its host, Laura Ingraham, 54, bullied high school student David Hogg.
JOBS
IN THE PRESS